<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00956332</url>
  </required_header>
  <id_info>
    <org_study_id>MGVS-MGA 002</org_study_id>
    <nct_id>NCT00956332</nct_id>
  </id_info>
  <brief_title>Safety Study of MultiGeneAngio in Patients With Chronic Critical Limb Ischemia</brief_title>
  <official_title>Phase I/IIa Safety, Two-dose Study of MultiGeneAngio in Patients With Chronic Critical Limb Ischemia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>MultiGene Vascular Systems Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>MultiGene Vascular Systems Ltd.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the safety and activity of two doses of&#xD;
      MultiGeneAngio, a cell therapy product produced from the patient's own cells, as potential&#xD;
      treatment for patients with chronic critical limb ischemia.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Approximately 16 million patients worldwide (1 in 20 people over the age of 50) suffer from&#xD;
      peripheral arterial disease(PAD). PAD is characterized by narrowing or occlusion of vessels&#xD;
      supplying blood to the lower limbs, most often due to atherosclerosis. Symptoms of PAD&#xD;
      include claudication that may progress to critical limb ischemia manifested by rest pain,&#xD;
      tissue loss and gangrene, which eventually may necessitate amputation.&#xD;
&#xD;
      MultiGeneAngio is a cell therapy-based product developed for treatment of patients with&#xD;
      chronic critical limb ischemia due to narrow or blocked leg arteries. MultiGeneAngio is&#xD;
      composed of endothelial and smooth muscle cells that are isolated from a short vein segment&#xD;
      harvested from the patient's arm. After isolation the cells are expanded, characterized, and&#xD;
      gene modified by transfer of angiogenic genes.&#xD;
&#xD;
      MultiGeneAngio is a clear cell suspension injected intra-arterially at the site of blockage&#xD;
      using a standard diagnostic catheter, in order to create and expand new collateral arteries,&#xD;
      and thereby improve blood flow to an ischemic limb.&#xD;
&#xD;
      Comprehensive pre-clinical studies, as well as clinical experience with PAD patients&#xD;
      suffering from claudication showed that production and administration of MultiGeneAngio was&#xD;
      feasible and safe, as no apparent drug-related adverse events have been observed. Moreover,&#xD;
      follow-up data of peak walking times imply a beneficial trend of this efficacy end-point.&#xD;
      Additional follow-up data will continue to be collected to help evaluate the safety and&#xD;
      efficacy of MultiGeneAngio.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>February 2010</start_date>
  <completion_date type="Anticipated">May 2026</completion_date>
  <primary_completion_date type="Actual">August 2011</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The safety of MultiGeneAngio will be assessed by monitoring adverse events</measure>
    <time_frame>Up to 15 years after treatment</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Improvement in critical limb ischemia symptoms</measure>
    <time_frame>Up to 3 months after treatment</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">28</enrollment>
  <condition>Peripheral Arterial Disease</condition>
  <condition>Peripheral Vascular Disease</condition>
  <condition>Critical Limb Ischemia</condition>
  <arm_group>
    <arm_group_label>MGA - Low therapeutic dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>MGA - Intermediate therapeutic dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>MultiGeneAngio</intervention_name>
    <description>Low-therapeutic dose of MultiGeneAngio in suspension administered as one treatment, intra-arterially</description>
    <arm_group_label>MGA - Low therapeutic dose</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>MultiGeneAngio</intervention_name>
    <description>Intermediate-therapeutic dose of MultiGeneAngio in suspension administered as one treatment, intra-arterially</description>
    <arm_group_label>MGA - Intermediate therapeutic dose</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Men and women 50 years of age or older&#xD;
&#xD;
          -  Ischemic rest pain (Rutherford category 4) and/or&#xD;
&#xD;
          -  Non-healing wounds (Rutherford category 5)&#xD;
&#xD;
          -  ABI of 0.5 or less, or TBI of 0.3 or less&#xD;
&#xD;
          -  Ankle systolic pressure of 70 mm Hg or less, or toe systolic pressure of 50 mm Hg or&#xD;
             less&#xD;
&#xD;
          -  Poor or no option for conventional revascularization&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Life expectancy of less than one year&#xD;
&#xD;
          -  Presence of significant inflow disease (&gt;50% stenosis) in the distal aorta, common or&#xD;
             external iliac&#xD;
&#xD;
          -  Advanced CLI, characterized by extensive tissue loss or gangrene (Rutherford category&#xD;
             6)&#xD;
&#xD;
          -  Previous major amputation on the leg to be treated or planned major amputation within&#xD;
             a month from enrollment&#xD;
&#xD;
          -  Evidence of osteomyelitis&#xD;
&#xD;
          -  Ischemic wounds with uncontrolled infectious symptoms&#xD;
&#xD;
          -  Heart angioplasty or CABG within 3 months prior to enrollment&#xD;
&#xD;
          -  Severe congestive heart failure (New York Heart Association stage IV)&#xD;
&#xD;
          -  Acute cardiovascular event within 3 months prior to enrollment&#xD;
&#xD;
          -  Uncontrolled blood pressure: SBP≥ 180 mmHg or DBP ≥110 mmHg&#xD;
&#xD;
          -  Known Buerger's disease&#xD;
&#xD;
          -  History of bleeding diathesis (e.g., hemophilia due to Factor VIII or IX deficiency)&#xD;
&#xD;
          -  Renal failure defined as a serum creatinine &gt;2.5mg/dL&#xD;
&#xD;
          -  Significant hepatic disease:&gt;3-fold elevation in ALT/AST, HBV or HCV carriers&#xD;
&#xD;
          -  Severe pulmonary disease&#xD;
&#xD;
          -  Active proliferative retinopathy and/or severe macular oedema&#xD;
&#xD;
          -  Intra-ocular surgery within 6 months prior to enrollment&#xD;
&#xD;
          -  Immunodeficient states (e.g. known HIV positivity, or organ transplant recipient) or&#xD;
             subject receiving immunosuppressive medication&#xD;
&#xD;
          -  History of malignant neoplasm (except curable non-melanoma skin malignancies) within 5&#xD;
             years prior to enrollment&#xD;
&#xD;
          -  Pregnant or lactating women&#xD;
&#xD;
          -  Previous treatment with angiogenic growth factors or stem cells&#xD;
&#xD;
          -  No demonstrable venous access&#xD;
&#xD;
          -  Known hypersensitivity to VEGF, Angiopoietin-1, or heparin&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sam L. Teichman, MD</last_name>
    <role>Study Director</role>
    <affiliation>Independent consultant</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Barzilai Medical Center</name>
      <address>
        <city>Ashkelon</city>
        <zip>78278</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Soroka Medical Center</name>
      <address>
        <city>Be'er Sheva</city>
        <zip>84101</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rambam Medical Center</name>
      <address>
        <city>Haifa</city>
        <zip>31096</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Shaare Zedek Medical Center</name>
      <address>
        <city>Jerusalem</city>
        <zip>91031</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hadassah University Hospital, Ein Kerem</name>
      <address>
        <city>Jerusalem</city>
        <zip>91120</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kaplan Medical Center</name>
      <address>
        <city>Rehovot</city>
        <zip>76100</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chaim Sheba Medical Center</name>
      <address>
        <city>Tel-Hashomer</city>
        <zip>52621</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Israel</country>
  </location_countries>
  <removed_countries>
    <country>United States</country>
  </removed_countries>
  <reference>
    <citation>Staudacher DL, Preis M, Lewis BS, Grossman PM, Flugelman MY. Cellular and molecular therapeutic modalities for arterial obstructive syndromes. Pharmacol Ther. 2006 Jan;109(1-2):263-73. Epub 2005 Oct 21. Review.</citation>
    <PMID>16243400</PMID>
  </reference>
  <reference>
    <citation>Gray BH, Conte MS, Dake MD, Jaff MR, Kandarpa K, Ramee SR, Rundback J, Waksman R; American Heart Association Writing Group 7. Atherosclerotic Peripheral Vascular Disease Symposium II: lower-extremity revascularization: state of the art. Circulation. 2008 Dec 16;118(25):2864-72. doi: 10.1161/CIRCULATIONAHA.108.191177. Erratum in: Circulation. 2009 Jun 30;119(25):e604.</citation>
    <PMID>19106409</PMID>
  </reference>
  <reference>
    <citation>Staudacher DL, Flugelman MY. Cell and gene therapies in cardiovascular disease with special focus on the no option patient. Curr Gene Ther. 2006 Dec;6(6):609-23. Review.</citation>
    <PMID>17168694</PMID>
  </reference>
  <reference>
    <citation>Gluzman Z, Koren B, Preis M, Cohen T, Tsaba A, Cosset FL, Shofti R, Lewis BS, Virmani R, Flugelman MY. Endothelial cells are activated by angiopoeitin-1 gene transfer and produce coordinated sprouting in vitro and arteriogenesis in vivo. Biochem Biophys Res Commun. 2007 Jul 27;359(2):263-8. Epub 2007 May 25.</citation>
    <PMID>17544375</PMID>
  </reference>
  <reference>
    <citation>Tongers J, Roncalli JG, Losordo DW. Therapeutic angiogenesis for critical limb ischemia: microvascular therapies coming of age. Circulation. 2008 Jul 1;118(1):9-16. doi: 10.1161/CIRCULATIONAHA.108.784371. Review.</citation>
    <PMID>18591450</PMID>
  </reference>
  <reference>
    <citation>Isner JM, Vale PR, Symes JF, Losordo DW. Assessment of risks associated with cardiovascular gene therapy in human subjects. Circ Res. 2001 Aug 31;89(5):389-400. Review.</citation>
    <PMID>11532899</PMID>
  </reference>
  <verification_date>March 2015</verification_date>
  <study_first_submitted>August 9, 2009</study_first_submitted>
  <study_first_submitted_qc>August 10, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 11, 2009</study_first_posted>
  <last_update_submitted>March 4, 2015</last_update_submitted>
  <last_update_submitted_qc>March 4, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 5, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Peripheral arterial disease (PAD)</keyword>
  <keyword>Peripheral vascular disease (PVD)</keyword>
  <keyword>Critical limb ischemia (CLI)</keyword>
  <keyword>Cell therapy</keyword>
  <keyword>Gene therapy</keyword>
  <keyword>Endothelial cells</keyword>
  <keyword>Smooth muscle cells</keyword>
  <keyword>Angiogenesis</keyword>
  <keyword>Arteriogenesis</keyword>
  <keyword>amputation</keyword>
  <keyword>diabetic foot</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vascular Diseases</mesh_term>
    <mesh_term>Peripheral Arterial Disease</mesh_term>
    <mesh_term>Peripheral Vascular Diseases</mesh_term>
    <mesh_term>Ischemia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

